CTLA4 and neoplasm: Their hydrogel‐based system showed that embedding autologous tumor and lymph node cells together generated personalised immune‐competent PDOs that recapitulated clinical responses to ICIs targeting PD‐1 and CTLA‐4 in 6 of 7 patients.87